Sionna Therapeutics (NASDAQ:SION) Stock Rating Lowered by Citizens Jmp

Sionna Therapeutics (NASDAQ:SION) was downgraded by stock analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday.

A number of other equities research analysts have also recently commented on SION. JonesTrading raised their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday. Guggenheim raised their price target on shares of Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Friday. Stifel Nicolaus reiterated a “hold” rating and issued a $7.00 price objective on shares of Sionna Therapeutics in a research report on Monday. Finally, Raymond James Financial lowered shares of Sionna Therapeutics from a “strong-buy” rating to a “market perform” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Stock Down 92.1%

Shares of SION stock traded down $46.98 on Monday, hitting $4.05. The company had a trading volume of 23,315,454 shares, compared to its average volume of 548,288. Sionna Therapeutics has a twelve month low of $4.01 and a twelve month high of $54.97. The firm has a market cap of $183.33 million, a P/E ratio of -1.88 and a beta of 1.32. The company has a 50-day moving average price of $42.35 and a 200-day moving average price of $40.42.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Equities research analysts expect that Sionna Therapeutics will post -2.63 EPS for the current year.

Insider Activity

In other news, Director Orbimed Advisors Llc sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 403,726 shares of company stock worth $18,259,354. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Several large investors have recently made changes to their positions in SION. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the 3rd quarter valued at $30,000. BNP Paribas Financial Markets acquired a new stake in Sionna Therapeutics during the 2nd quarter worth $31,000. State of Wyoming purchased a new stake in shares of Sionna Therapeutics during the second quarter worth $35,000. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at about $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Sionna Therapeutics in the second quarter worth about $44,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.